Bayer

Fair value measurement information under IFRS

IFRS 13 “Fair value measurement” sets out a single consistent framework for measuring fair value within IFRS financial statements and outlines a standardised set of disclosures in respect of fair value measurements. IFRS 13 has been mandatory now for some years, with application being required for annual reporting periods beginning on or after 1 January 2013. This report sets out the results of how requirements of the standard have been put into practice, both in terms of measurement and disclosure, in the consolidated financial statements of 139 large public limited companies with year ends between 31 March 2016 and 1 April 2017. It is not an exhaustive study of all aspects of IFRS 13 application and its conclusions are limited to our findings in respect of the areas analysed within the financial statements reviewed.

Disclosure of the impacts of IFRS 16 "Leases"

IFRS 16 “Leases” will fundamentally change accounting by lessees as it requires assets previously off balance sheet under operating lease arrangements to be brought on balance sheet as is currently the case for finance leased assets. As a result on application companies will recognise both additional assets and additional liabilities. Consequently there will also be knock on effects in the income statement as operating lease charges are replaced by a depreciation charge and a finance expense. This report analyses the financial statements of a range of companies to firstly establish whether there has been any early adoption and secondly to establish what companies are disclosing in respect of IFRS 16 and its future impacts.

Bayer AG Monitor

Bayer AG Annual Report 2016
CR Monitor Issue: 
2017/0502
Company covered: 
Bayer AG
Period End: 
31 December, 2016
Report issued on 2 May 2017 covered the following practice issues:
Change
Change in reporting segments following the introduction of new organisational structure.
Change
Results of discontinued operations analysed by business.
Pronouncements
Introduction of discussion of key audit matters in the auditor’s report.

Provisions & contingencies - Bayer AG

Period End: 
31 December, 2014
Period End Date: 
2014-12-31
Listing Status: 
S&P Europe 350
ICB Industry Classification: 
1353 Commodity Chemicals
Auditor: 
PricewaterhouseCoopers

Provisions & contingencies - Bayer AG

Period End: 
31 December, 2014
Period End Date: 
2014-12-31
Listing Status: 
S&P Europe 350
ICB Industry Classification: 
1353 Commodity Chemicals
Auditor: 
PricewaterhouseCoopers

Hedge accounting - Bayer AG

Period End: 
31 December 2013
Period End Date: 
2013-12-31
Listing Status: 
S&P Europe 350
ICB Industry Classification: 
1353 Commodity Chemicals
Auditor: 
PricewaterhouseCoopers
Annual Report: 

Employment termination benefits: An emerging issue under IFRS

This report covers the accounting treatment of termination benefits in light of additional guidance given by a revised version of IAS 19 “Employee benefits”. It considers changes in classification and recognition of amounts linked to termination benefits and disclosure of the financial impacts arising from related changes in policy.  

Research and development - Bayer AG

Period End: 
31 December 2013
Period End Date: 
2013-12-31
Listing Status: 
S&P Europe 350
ICB Industry Classification: 
1353 Commodity Chemicals
Auditor: 
PricewaterhouseCoopers